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Acute, severe and anaphylactoid reactions are very rare
with low-molecular-weight iron dextran, CosmoFer
R 
Sir,
It was with interest and surprise that I read the article by
Liliana Schaefer and Roland M Schaefer [1].
In this article, Liliana and Roland Schaefer do not dis-
tinguish between the adverse drug event profile of the old
high-molecular-weight iron dextrans that have been with-
drawn from the market of Europe ∼20 years ago and the
low-molecular-weight iron dextran marketed in 1992 as
INFeD
R  in the US and in 2001 as CosmoFer
R  in Europe
and overseas. The product is produced by Pharmacosmos
in Denmark and marketed in more than 40 countries.
Numerous articles, [2–7], including the Chertow arti-
cle [5] referenced by the Schaefers, document that the
high-molecular-weight iron dextran has many times more
adverse drug events than the low-molecular-weight iron
dextran. The high-molecular-weight iron dextran is today
marketed practically only in the USA under the brand Dex-
ferrum where the active pharmaceutical ingredient is pro-
duced by Vifor International. Vifor also produces iron su-
crose Venofer
R .
Low-molecular-weight iron dextrans have now been ad-
ministered in more than 70 million doses of 100 mg. The
CosmoFer
R  SmPCinEuropewasupdatedinJune2007and
concludes that anaphylactoid reactions are less than one in
ten thousand; this is the same as in the SmPC for Venofer
R 
iron sucrose.
IwouldexpectthatthenextrevisionoftheEuropeanBest
Practice Guidelines reflects the updated knowledge about
low-molecular-weight iron dextran, CosmoFer
R .
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Reply
Sir,
We appreciate the interest of O. Vaage-Nilsen who claims
that in our article [1] we had not distinguished between
high-molecular-weight (Dexferrum
R 
) and low-molecular-
weight (INFed
R 
) dextran. This of course is not the case.
We were quoting an article by Chertow et al. [2], of which
Mr Vaage-Nilsen is an author as well, clearly showing
that the reported numbers of life-threatening events over a
3-year period were 6/10.000.000 with iron sucrose versus
33/10.000.000 for the INFed iron dextran. Rare events in-
deed, but still a striking difference nonetheless. For these
reasons the European Best Practice Guidelines—published
in this learned journal do discourage the use of all iron
dextran species, irrespective of their molecular weight [3].
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